Business Wire

ANT-GROUP

3.11.2022 04:21:38 CET | Business Wire | Press release

Share
Ant Group Launches Alipay+ D-store™ Solution at Singapore FinTech Festival 2022

Ant Group today officially launched its Alipay+ D-store™ at the Singapore FinTech Festival 2022. Alipay+ D-store™ is a business digitalization solution designed to support the service industry, especially brick-and-mortar businesses to digitalize their operations to boost efficiency and productivity.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221102006207/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Photo: Business Wire)

An integrated one-stop solution which businesses can use to build digital stores across multiple digital platforms in a fast, scalable and cost-efficient way, Alipay+ D-store™ provides a suite of toolkits to digitalize merchants' payments, operations, services and marketing, unlocking new revenue opportunities and delivering better services to consumers.

Businesses could have digital stores on digital platforms in the form of mini programmes. Digital stores could also be developed as H5 pages and easily embedded in social media and online to reach consumers. Digital platforms currently partnering with Alipay+ D-store™ include Chope, Alipay, Touch 'n Go eWallet, AlipayHK, etc.

“We welcome more digital platforms to collaborate to accelerate the digitalization of the global service industry together,” Dr. Cherry Huang, Global Head of Alipay+ D-store™ said.

“Leveraging digital solutions is critical for the service industries to boost operational efficiency and adapt to the fast-changing market conditions. The Alipay+ D-store™ solution is developed with the goal to make it easier for brick-and-mortar businesses to go digital at scale, so that businesses can better serve and engage digital-savvy consumers by providing a seamless omni-channel experience,” she added.

Having identified the F&B industry a priority sector, Alipay+ D-store™ solution has been adopted by brands including fast food chain Burger King, Koufu, one of Singapore’s most established and largest operators and managers of food courts and coffee shops, and more than 2,000 local restaurants, cafes and eateries in Singapore, Malaysia, Hong Kong SAR, China and other markets.

At the Festival, Alipay+ D-store™ also unveiled its newest customer, Huggs Coffee, one of Singapore’s largest homegrown cafe chain brands specializing in coffee with over 20 outlets. Huggs will work with Alipay+ D-store™ to digitalize its outlets and operations efficacy, allowing customers to access seamless services through its digital store on Chope and other platforms in future.

Speaking in regard to the partnership, Lee Haoming, Managing Director of Huggs Coffee said: “Huggs is not only a business of F&B, to us, a good cup of coffee is a tool to create social connections. That is why creating a unique and elevated experience beyond the coffee itself is important to Huggs, and we believe digitalization plays an important role in enhancing the experience.”

“We are very excited to partner with Alipay+ D-store™ to transform the Huggs experience! It creates a more efficient operation flow to brew more smiles while reducing time to queue and pay, henceforth allowing our valued customers to spend more quality time on building connections with each other when visiting Huggs.”

To learn more about Alipay+ D-store™ at the Singapore FinTech Festival 2022, visit the Ant Group booth #2E01, or attend the product showcase “It’s A PLUS: How Alipay+ & Partners Build Digital Resilience For Businesses” scheduled at 11:20 a.m., 3 November in Hall 3.

About Ant Group

Ant Group aims to build the infrastructure and platforms to support the digital transformation of the service industry. Through continuous innovation, it strives to provide all consumers and small and micro businesses equal access to digital, financial, and other daily life services that are convenient, sustainable, and inclusive.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221102006207/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye